Conclusions: This prospective pilot study provides preliminary evidence that MCP-1 levels are significantly elevated in AIS and are associated with NIHSS change during hospitalization and unfavorable outcome at 6-month follow-up. Here, CCL2 is linked to androgen insensitivity syndrome.